A Phase II study of M605106 for axillary osmidrosis
Phase 2
Completed
- Conditions
- axillary osmidrosis
- Registration Number
- JPRN-jRCT2031200184
- Lead Sponsor
- Infomation Trials Clinical
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
axillary osmidrosis patients
Exclusion Criteria
(1)Not suitable for application of investigational drug from the viewpoint of safety, such as a wound on the axilla, or patients with complications or abnormal findings on the axilla affecting safety assessment.
(2)Patients judged by the investigator or sub-investigator to have a degree of odor(other than axillary odor) that may affect the evaluation of axillary odor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does M605106 target in axillary osmidrosis treatment?
How does M605106 compare to standard-of-care treatments for axillary osmidrosis in clinical efficacy?
Are there specific biomarkers that predict patient response to M605106 therapy for axillary osmidrosis?
What are the potential adverse events associated with M605106 in phase II trials for axillary osmidrosis?
What are the current combination therapies or competitor drugs for axillary osmidrosis treatment alongside M605106?